Skip To Main Content
Campus
  • Tiede
  • Materiaalit
Campus
  • Tiede
  • Materiaalit

Artikkelit

Järjestä

Suodattimet

Nollaa
  • Terapia-alue

Why Choose Toujeo® (Insulin Glargine)

Lue lisää

Fabry disease

Fabry disease is an X-linked lysosomal storage disease due to a defect in the gene encoding the lysosomal enzyme alpha-galactosidase A (α-Gal A), causing progressive cellular accumulation of the substrate globotriaosylceramide (GL-3) and globo-triaosylsphingosine (lyso-GL-3).

Lue lisää

How to diagnose Fabry

Think Fabry, think timely testing first.

Lue lisää

Monitoring disease progression

Think Fabry, think regular profile-based assessments.

Lue lisää

Cardiac involvement in Fabry disease

Cardiovascular disease is the leading cause of death in fabry disease patients.1 Undiagnosed and untreated Fabry disease leads to progressive, irreversible, life-threatening heart injury.2,3

Lue lisää

Renal involvement in Fabry disease

Think Fabry, think renal involvement that may present early in life and could go undetected.

Lue lisää

Family screening

Think Fabry, think screening at-risk family members.1

Lue lisää

When to treat

Think Fabry, think early treatment to help slow or prevent life-threatening disease progression.1,2

Lue lisää

Pooled analysis: Interventional and observational studies

A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/ without prior use of glucagon-like peptide-1 receptor agonist therapy.1

Lue lisää

How to Use Toujeo®

Lue lisää

What is Toujeo?

Lue lisää

Atopic dermatitis pathophysiology: type 2 inflammation & cytokines

Beneath the skin of patients with AD—type 2 inflammation and the cytokines involved.

Lue lisää